Venture-backed Clementia raises $152 mln in Nasdaq debut
Montréal biopharmaceutical company Clementia Pharmaceuticals Inc last week raised about $152 million (US$120 million) from its initial public offering on the Nasdaq Global Market. The news was noted by BDC Capital Healthcare Fund, an investor in Clementia since 2012. The company's other backers include Fonds de solidarité FTQ, Janus Henderson, OrbiMed Advisors and New Enterprise Associates. Clementia's IPO is the second completed this year by a Canadian life sciences company. In May, Vancouver's Zymeworks Inc secured about $86 million (US$64 million) from its Canadian and U.S. offering.
9 August 2017•3 mins read
